CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination

por Brown, Victoria E, Moore, Sydney L, Chen, Maxine, House, Nealia, Ramsden, Philip, Wu, Hsin-Jung, Ribich, Scott, Grassian, Alexandra R, Choi, Yoon Jong
Publicado 2023

A Medium-Throughput Single Cell CRISPR-Cas9 Assay to Assess Gene Essentiality

por Grassian, A. R., Scales, T. M. E., Knutson, S. K., Kuntz, K. W., McCarthy, N. J., Lowe, C. E., Moore, J. D., Copeland, R. A., Keilhack, H., Smith, J. J., Wickenden, J. A., Ribich, S.
Publicado 2015

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma

por Kawano, Satoshi, Grassian, Alexandra R., Tsuda, Masumi, Knutson, Sarah K., Warholic, Natalie M., Kuznetsov, Galina, Xu, Shanqin, Xiao, Yonghong, Pollock, Roy M., Smith, Jesse S., Kuntz, Kevin K., Ribich, Scott, Minoshima, Yukinori, Matsui, Junji, Copeland, Robert A., Tanaka, Shinya, Keilhack, Heike
Publicado 2016

Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma

por Kawano, Satoshi, Grassian, Alexandra R., Tsuda, Masumi, Knutson, Sarah K., Warholic, Natalie M., Kuznetsov, Galina, Xu, Shanqin, Xiao, Yonghong, Pollock, Roy M., Smith, Jesse J., Kuntz, Kevin W., Ribich, Scott, Minoshima, Yukinori, Matsui, Junji, Copeland, Robert A., Tanaka, Shinya, Keilhack, Heike
Publicado 2017

Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma

por Drew, Allison E., Moradei, Oscar, Jacques, Suzanne L., Rioux, Nathalie, Boriack-Sjodin, Ann P., Allain, Christina, Scott, Margaret Porter, Jin, Lei, Raimondi, Alejandra, Handler, Jessica L., Ott, Heidi M., Kruger, Ryan G., McCabe, Michael T., Sneeringer, Christopher, Riera, Thomas, Shapiro, Gideon, Waters, Nigel J., Mitchell, Lorna H., Duncan, Kenneth W., Moyer, Mikel P., Copeland, Robert A., Smith, Jesse, Chesworth, Richard, Ribich, Scott A.
Publicado 2017

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation

por Thomenius, Michael J., Totman, Jennifer, Harvey, Darren, Mitchell, Lorna H., Riera, Thomas V., Cosmopoulos, Kat, Grassian, Alexandra R., Klaus, Christine, Foley, Megan, Admirand, Elizabeth A., Jahic, Haris, Majer, Christina, Wigle, Tim, Jacques, Suzanne L., Gureasko, Jodi, Brach, Dorothy, Lingaraj, Trupti, West, Kip, Smith, Sherri, Rioux, Nathalie, Waters, Nigel J., Tang, Cuyue, Raimondi, Alejandra, Munchhof, Michael, Mills, James E., Ribich, Scott, Porter Scott, Margaret, Kuntz, Kevin W., Janzen, William P., Moyer, Mikel, Smith, Jesse J., Chesworth, Richard, Copeland, Robert A., Boriack-Sjodin, P. Ann
Publicado 2018